Strides Pharma Science Limited (STAR) Earnings Call Transcript & Summary

October 30, 2026

National Stock Exchange of India IN Health Care Pharmaceuticals earnings 56 min

Earnings Call Speaker Segments

Operator

operator
#1

Good afternoon, everyone, and welcome to the Q2 FY ’27 earnings conference call for Strides Pharma Science Limited. Just a reminder that every participant line will be in listen-only mode, and once the presentation wraps up, you'll have a chance to ask questions. <<operator_script>> Kindly be aware that this conference is being recorded. At this point I'll turn the call over to Mr. Abhishek. Thanks, and the floor is yours, sir.

Abhishek Singhal

executive
#2

Thanks, Nazli <<inaudible>>. Good morning, everyone, and thanks for being with us on today's Strides earnings call covering the second quarter and the half-year that closed in September 2026. Joining us are Badree, our Managing Director and Group CEO, along with Vikesh, our Group CFO, and they'll walk you through the business highlights and the financials for this quarter. I trust you've had a chance to look at our results release and the quarterly investor presentation, both of which are now up on our website and on the Stock Exchange website. A transcript of this call should be posted on the company's website within a week. Just a reminder that what we discuss today could include forward-looking statements, and it should be considered alongside the risks that apply to our business. If any questions come up after this call wraps up, don't hesitate to get in touch with the Investor Relations team. With that, I'll turn things over to Mr. Badree for his opening remarks.

Badree Komandur

executive
#3

Thank you, Abhishek. Good morning, good afternoon, and good evening everyone, and a warm welcome to the Strides Q2 and H1 FY ’27 earnings call. Thank you for joining us and for the trust and support so many of you have shown us over the years. As always, I’ll begin with the overview of the quarter, and I’ll share an update of our overall FY ’28 aspiration, followed by our U.S. and ex-U.S. business. Vikesh will then take you through the financial performance in greater detail, after which we’ll be happy to take your questions. Q2 FY ’27 has been a quarter of firsts for Strides. We delivered our highest quarterly revenue, and for the first time in our history, our ex-U.S. business became larger than our U.S. business, a milestone we had set for FY ’28 and have reached well ahead of the schedule. Let me share the headline first. Our overall FY ’28 growth aspiration remains intact. Our rest of the business is accelerating fast, faster than the U.S., and well ahead of the schedule. Let me say that again, our overall revenue ambition for FY ’28 is firmly in place. What will change is the regional mix, with ex-U.S.

Badree Komandur

executive
#4

We're speeding up, and we're speeding up faster than the U.S. Our target for ex-U.S. was to match the U.S. by FY ’28, and we've hit that already in Q2 of FY ’27. As we pointed out last quarter, we expect H2 to come in stronger than H1. On the Q2 FY ’27 performance, I'll go over the main highlights. So with that, let me walk you through the quarter, and I'm very pleased to share that we had a strong second quarter. Revenue for Q2 FY ’27 came in at INR14,297 million, our highest ever, up 17% year-on-year and 13% quarter-on-quarter, driven by our ex-U.S. business, and achieved against a tough macro backdrop. Ex-U.S. now accounts for 49% of our revenues, compared with 43% in Q2 of last year, a clear signal that our diversification strategy is paying off. Absolute gross margins rose a healthy 13% year-on-year to INR 8,003 million, and gross margin was 56% versus 57.8% in Q2 last year and 60.9% in Q1 this year, reflecting higher input cost tied to the geopolitical situation. EBITDA was up 8% year-on-year to INR2,509 million, passing the INR2,500 million mark in a single quarter for the first time. That's another milestone for Strides . EBITDA margin came in at 17.6% against 19% in Q2 last year and 18.2% in Q1, as we absorb the elevated material, freight, and logistics costs tied to that same geopolitical situation.

Badree Komandur

executive
#5

We're actively tackling these cost pressures through alternative sourcing, procurement initiatives, and ongoing cost optimization efforts throughout the business, and we're confident in our ability to manage them. Operational PAT rose a strong 12% year-on-year to INR1,358 million, and operational EPS increased to INR14.7 from INR13.2 in Q2 of last year. Before I turn to our individual businesses, let me step back and provide an update on our FY ’28 aspiration, which many of you will have already seen in our presentation. Let me start with our track record, because I think it tells our story better than any words I could use. Across the last 10 quarters since Q1 FY ’25, we've delivered steady and predictable growth across key metrics. Revenue has compounded at about 14%, EBITDA at about 13%, and operational PAT at about 41%. That consistency gives us real confidence as we enter the next phase of our growth. We had shared an aspiration of about 375 million in U.S. regional revenue by FY ’28. Given how the market has evolved, we now expect to reach this a little beyond FY ’28. The timing has moved, the ambition has not.

Badree Komandur

executive
#6

What matters most here is that our ambition for growth across the remainder of the company is completely unchanged. Outside the U.S., the market is gaining momentum faster than we had planned, and we look to Strides to carry the overall top-line expansion together with its profitability. Where the U.S. is concerned, the only element that has shifted is the timing. That business is still expanding, though at a more deliberate rate, and the causes sit in the marketplace rather than in how committed we are. Several developments have occurred since we first stated that aspiration. To begin with, the drug shortage opportunities in oral solids, which gave the industry a lift back then, have for the most part normalized. Next, operating costs have risen, reflecting higher material cost as well as our choice to carry more inventory so we can maintain the industry-leading service levels we provide. We likewise decided against launching products that fell short of our margin profile, which safeguards profitability. And third, growth in controlled substances is held back by quota allocation, which we anticipate will improve progressively. Our answer follows from our core business philosophy and stands on three pillars. The first is growth led by profitability. We will safeguard our established profitability thresholds and generate margin-accretive revenues via selective launches and a growing set of differentiated platforms. We will not trade away the profitability or the quality of our business in order to chase revenue.

Badree Komandur

executive
#7

Second, we're rebalancing our growth engines, placing a sharper emphasis on markets outside the U.S. to drive geographic diversification and speed up overall growth. And third, the U.S. stays a strategic growth market for us, with that growth anchored in differentiated platforms like nasal sprays, patches, films, and a steadily expanding controlled substance portfolio. Although our U.S. business has continued to serve as an anchor, the ex-U.S. business has matured right alongside it. That's where we're seeing genuine acceleration. In H1 FY ’27, our ex-U.S. business grew 24%. Our target is for ex-U.S. revenue to match the U.S. by FY ’28. Ex-U.S. represented 76% of the U.S. business in FY ’25, 90% in FY ’26, and in Q2 FY ’27 it hit 102%, overtaking the U.S. well ahead of schedule. That's a strategy we've pursued patiently for years, and it's now coming to life. Ex-U.S. today stands equal with the U.S. — not in place of it, but alongside it, and the market — and that makes Strides stronger as a whole. With growing scale, operating leverage, and a better portfolio mix, we anticipate continued margin expansion in the business. As a result, we now have two strong growth engines, both pointed in the same direction.

Badree Komandur

executive
#8

The U.S. operation is the bedrock of our company: it has leading positions in the market, a wide range of approved products, and a pipeline that keeps expanding with differentiated and controlled substance offerings. The business outside the U.S. serves as our growth driver, with a solid footprint spanning Europe, the U.K., the Nordics and Africa, a powerful launch engine, and a long runway into new territories. A shared discipline powers both: a deep pipeline, consistent launches, and an unwavering commitment to serving our customers. These two engines do not compete; each one reinforces the other. They provide additional avenues for growth and make us more diversified and resilient. With that said, let me walk you through the U.S. business. Q2 revenue came in at INR6,855 million, or $73 million <<inaudible>>, which represents 9% growth year-on-year and 9% quarter-on-quarter. U.S. revenue for H1 was INR13,137 million, up 7% year-on-year. As we noted on our previous call, we anticipated a softer first half, and the healthy sequential recovery we achieved this quarter is encouraging to me. Our B2B partner business had a strong order book, and we landed meaningful new business wins during the year — from a partner product, our recent launches, and other key molecules in our portfolio.

Badree Komandur

executive
#9

Those gains are going to start appearing in how we perform across the next several quarters, and they support the stronger H2 that we've been discussing. We keep providing service levels that lead the industry for every one of our customers. That genuinely sets us apart from competitors, and it's essential when it comes to winning and keeping business with some of the biggest customers and partners in the market. A solid foundation comes from our portfolio. As of October 26th, we have filed 230 ANDAs, and 212 of those have been approved, covering 154 products. We also hold a basket of ANDAs that haven't been launched yet, and we'll bring those to market when the timing is opportune. In the quarter, we launched three products, which brought our commercial portfolio to 75 products, compared with 72 at the close of Q1. We now rank in the top 3 for 38 products, and those products together account for roughly 70% of our revenues. As I said earlier, our U.S. portfolio is steadily moving toward differentiated products with higher margins. Our active pipeline contains more than 40 value-accretive products, with filings and approvals planned in a phased manner and commercial — commercialization through FY ’30. Controlled substances are a key element of the strategy, and we believe the opportunity ahead is much larger.

Badree Komandur

executive
#10

In Q2, customer orders rose for our CS business, and right now the five CS products we’ve commercialized — all of them oral solid tablets — account for 6% of revenues and serve a market worth roughly $750 million. Quota allocation does limit this portfolio, but we have over 10 CS products in the pipeline spanning several domains, such as nasal sprays, patches, and films, and those will grow our addressable market to approximately 4.5 billion — about 6 times the market we serve today. Importantly, limited API quota is all these niche products require, so they can drive the ramp-up of this business even within today’s allocations. We also hold an advantage that takes years to build. Regulators require these products to be manufactured in the U.S., and our Chestnut Ridge facility already has the capacity and expertise to do exactly that. Beyond the controlled substances, we have more than 25 non-CS products to strengthen our core portfolio. Together, these products are set to broaden our addressable market, deepen our portfolio differentiation, and create exciting medium to long-term growth opportunities. Our near-term milestones are already in sight. We continue to invest in building our nasal spray portfolio, and as committed in our last call, we filed our third nasal spray, also a controlled substance.

Badree Komandur

executive
#11

Back in September 2026. For our nasal spray, the GDUFA goal date falls in H2 FY ’27, and we're looking at approval during Q4. On transdermal patches, a controlled substance patch should launch in Q3. That product arrived as part of the ANDAs we acquired, and we anticipate its full benefit flowing in during FY ’28. All told, we expect a stronger H2 for the U.S. business. We are committed, we are invested, and we are building for the long term, growing in a disciplined way that protects the quality of our earnings. Turning to the ex-U.S. markets, our accelerator, the most exciting part of our story. The ex-U.S. market for Q2 reached INR6,963 million. An outstanding 31% growth year-on-year. For H1, the revenue was INR12,838 million, up 24% year-on-year. Importantly, even as the ex-U.S. markets grew faster than the company average, we maintained the profitability of this business. What encourages me most is how broad the growth is. Every ex-U.S. market continues to show healthy momentum driven by new product launches and expansion of our core base into new geographical — into new geographies and with new partners. In Q1, we had said that certain shipment delays were a matter of timing and not demand.

Badree Komandur

executive
#12

I'm happy to report that thanks to strong execution across the supply chain, we shipped Q2 with no spillovers on demand, and order books in our key U.S. markets remain quite healthy. Over in the U.K., the prescription business turned in a strong performance, with healthy pricing and volume momentum across several key molecules. We keep deepening ties with the market's leading wholesalers, which positions us as a reliable supply partner. We expect to launch — we expect launch momentum to build here and to drive the next leg of growth. In Europe, the partnered business performed strongly on the back of higher customer uptake. Our private label business, the OTC business in Germany, keeps growing strongly, with wider pharmacy reach and an expanding product portfolio. We're adding new customers across several countries, plus multiple new out-licensing deals signed in the first half, which will strengthen our momentum further. Focused R&D investments and a broader customer base will keep fueling growth in that region. The Nordics posted strong quarter-on-quarter growth, led by a base portfolio. Our branded prescription business is showing very encouraging early signs in the market — in-market uptake — with some of our branded products now positioned as first-line treatment across several regions in Denmark, and more regions expected to follow.

Badree Komandur

executive
#13

Alongside that rising launch momentum, our branded portfolio has been broadened to fuel growth across the Nordics during the second half. In Australia, the supply contract got substantially better, and with our key partners we've agreed on new projects that are currently at differing stages of implementation. Within Africa, our branded business across Francophone Africa posted outstanding growth, and we keep outpacing the underlying market. Our transaction with Sandoz is presently awaiting antitrust clearances in a few countries, and we anticipate closing it in Q3. In South Africa, we witnessed robust momentum within the independent pharmacy channel and introduced additional products plus new business with a leading retail pharmacy chain. Broadly speaking, the robust launch pipeline along with a growing customer base and major regulatory filings in progress — is in progress throughout all our territories. We anticipate the entire ex-U.S. business will continue expanding more quickly than the company average. Before wrapping up, I'm happy to share a significant governance update. It's our pleasure to welcome Mr. Biren Gabhawala to the board as an Independent Director. Biren is a chartered accountant possessing over three decades of experience spanning financial reporting, audit, taxation, and corporate governance. And he has chaired the audit committee of eClerx Services and 3M India.

Badree Komandur

executive
#14

Adding this director will reinforce the board's financial supervision even more, and as a result, Independent Directors will now account for six out of our 10 Directors. Biren, we're glad to have you at Strides. Before Vikesh takes over, allow me to give you one unambiguous takeaway: our broader growth narrative remains intact. Although our U.S. ambition is going to need somewhat more time, our dedication to growth has not changed. We'll keep chasing top-line expansion across geographies without sacrificing profitability. Our dedication to the U.S. is just as unchanged. It stays a core market, a central pillar of our growth, and a home to some of the most exciting opportunities in our pipeline. Our U.S. business is strong, our business outside the U.S. is accelerating, and combined they give us more ways to grow than at any point of time in our history. With that, I'll hand things over to Vikesh, who will walk you through the financial performance. Vikesh, over to you.

Vikesh Kumar

executive
#15

Thank you, Badree. Good morning, good afternoon, and good evening, and thanks to all of you for being with us. Badree has walked us through the headline performance for the quarter. My focus will be on what drove our profitability, cash flows, and balance sheet metrics. Beginning with gross margins, material costs climbed to 44% of revenues in Q2, up from 42% — 42.2% a year earlier, which reflects the raw material cost increase that Badree described. That moderated our gross margins to 56% for Q2. Importantly, gross margins for the first half came in at a healthy 58.3%. Our ex-U.S. businesses, where we have kept profitability intact even as it scaled, continue to support the quality of our margins. With cost increases now easing and our cost improvement programs — including alternate sourcing and procurement initiatives — gaining traction, we are confident of sustaining our H1 gross margins going forward. Even in this challenging environment, we stay — we stay committed to our margin discipline, launching only products that meet our profitability threshold and continuing to focus on the quality of our revenue growth. EBITDA for the quarter was INR 251 crores, our highest ever, at a margin of 17.6%. Higher material, freight, and supply chain costs tied to the geopolitical situation compressed our margins and tempered the flow-through of our very strong revenue growth, but it did not hold back the growth in our absolute profitability.

Vikesh Kumar

executive
#16

So with both growth engines — the U.S. and ex-U.S. — now pitching in evenly, our earnings base has never been more diversified or resilient. Turning to operating costs: other operating costs, leaving out freight, rose by INR47 crores year-on-year, driven by higher manufacturing costs and other operating costs within manufacturing. Freight costs, meanwhile, went up INR21 crores year-on-year, reaching 5.5% of revenues. Despite those increases, operating leverage remains evident, since total operating costs came down by 40 basis points to 38.4% of revenues. Looking at the cost line items below EBITDA, depreciation and amortization stood at INR57 crores for the quarter, while net finance cost was INR43 crores — a bit higher because of the larger average working capital borrowings during the quarter. Operational PAT rose a healthy 11.5% year-on-year to INR136 crores, with operational EPS of INR14.7 per share, and our conversion of EBITDA to operational PAT holds steady at 54%. Reported PAT came in at INR134 crores for the quarter, with reported EPS of INR14.2 per share. From an H1 standpoint, the first half posted steady growth across all our key metrics. H1 FY ’27 revenues were up 15.1% to INR2,695 crores. EBITDA increased 6.9% to INR481 crores at a 17.8% EBITDA margin, and operational PAT rose 9.8% to INR259 crores, with operational EPS of INR28.1 per share.

Vikesh Kumar

executive
#17

For the first half, reported PAT came in at INR300 crores, marking a 26.4% increase. That figure also took in the gain from the Pivot Path divestment, which we booked in Q1. Turning to working capital, the cash-to-cash cycle came to 137 days. That's 13 days more than March 2026, and absolute working capital rose by INR307 crores in the first half. Two things explain this: inventory investment made to offset longer supply chain timelines, and the working capital that backed our growth. Roughly INR174 crores of that reflects the 14-day rise in inventory levels versus Q4. Higher transit and lead times stemming from the geopolitical situation drove this, and we also intentionally built up finished goods inventories across all our front-end locations. That has helped us return to industry-leading service levels despite a tough operating environment. Those service levels were key to the new business wins we landed in the U.S. this quarter, and to delivering growth in our ex-U.S. markets as well. The other INR133 crore of working capital increase comes from the 15% revenue growth we posted in H1. We stay committed to steadily improving our cash-to-cash cycle and bringing it back to our historic levels.

Vikesh Kumar

executive
#18

Regarding net debt, as we said before, the inventory buildup across the past two quarters was anticipated to raise our net debt-to-EBITDA ratio on a temporary basis. That ratio is now 1.72 times, which reflects a rise of INR211 crores in net debt through H1, primarily from working capital. Meanwhile, we keep putting money into our future, with INR208 crores deployed in capex and intangibles to back our growth platforms, among them our nasal spray and transdermal patch programs. Those investments target the differentiated pipeline Badree described, including our controlled substances opportunity, which is set to widen our addressable market and support margin-accretive growth. As inventory returns to normal and H2 launches and business wins start to contribute, we stay — we remain focused on growth and on enhancing our cash-to-cash cycle. Accordingly, we anticipate our net debt-to-EBITDA ratio will stabilize and improve by year-end. This net debt figure does not account for the retained investment we hold in OneSource, which is now valued at roughly INR290 crores. Turning to ROCE, our trailing 12 month ROCE came in at 14.4%, still within the 14% to 15% range. As growth — as our growth carries on and recent investments mature, we expect those returns to get better.

Vikesh Kumar

executive
#19

So in summary, Q2 brought record revenues and EBITDA despite a tough cost backdrop, and during the first half we saw consistent growth across every one of our key metrics, with the U.S. and ex-U.S. businesses both contributing side by side. Looking ahead to the second half, our priorities are clear: build on — build on the momentum we have in these markets, protect our gross margins, make our cash-to-cash cycle better, and reinforce our net debt-to-EBITDA ratio. With the overall growth aspiration for FY ’28 still intact and operating leverage coming through, we keep maintaining that the bottom line should accelerate ahead of the top line. We have confidence in how strong our business is and in our capacity to deliver on these priorities. Thank you, and we are now happy to take your questions.

Abhishek Singhal

executive
#20

Nazli, let’s move on to questions — we’re ready for Q&A now.

Operator

operator
#21

Yes, sir. Thanks a lot. We'll now start the question-and-answer portion. <<operator_script>> Our first question comes from Nitin Agarwal at DAM Capital. Go ahead, please.

Nitin Agarwal

analyst
#22

Appreciate you taking my question. Badree, in your opening remarks you already touched on the pickup that’s occurring in markets outside the U.S. But I have two things. First, A, could you give us a sense of what’s driving this stronger momentum in the non-U.S. markets? And second, what sort of growth is achievable in those markets across the next 2 to 3 years, particularly when you factor in the Sandoz transaction that you closed, as you mentioned, at some point this year?

Badree Komandur

executive
#23

So regarding markets outside the U.S., this is a space we've put money into over a very long stretch. Growth in new territories and expansion of the portfolio are what drive these markets. Some are B2C markets, some are B2B markets. And demand is rising, in our view. We think those are the two main factors behind our feeling that this market can grow. We've got a portfolio ready, products ready, and regulatory hurdles are quite minimal from a commercial revenue perspective. We're also putting investment into domains in these markets. Overall, I'd say it's all coming together quite nicely. That covers the first part. When it comes to growth in this market, we'll keep growing well above the company average across all of these markets. On the higher side, in the last few conversations we've consistently said this market will grow faster than the U.S. market, and we believe that trend will carry on. And this trend is certain to carry on for the near long-term. And with Sandoz adding in, it will definitely result in a very, very meaningful size over the next one or two years.

Badree Komandur

executive
#24

And we're quite confident about mirroring the U.S. market when it comes to the aspiration. That aspiration was one we set roughly 2 years ago from a 375 million standpoint, and given the latest trends emerging in non-U.S. markets, it ought to be above that.

Nitin Agarwal

analyst
#25

So you're saying it should be more than 375 by FY ’28, if I understood that correctly?

Badree Komandur

executive
#26

You've got that right.

Nitin Agarwal

analyst
#27

And when it comes to these markets, what's fueling that growth — are certain products behind it, or is it more of a broad-based product portfolio that's driving it?

Badree Komandur

executive
#28

The portfolio is quite broad-based. As I mentioned, we have B2C markets and B2B markets. The positive aspect, I think, is that it's very sticky and very consistent. So once you get to a certain size, that stickiness becomes much, much greater. And our product strategy has worked out across all of these markets. In B2C markets, actually, many markets sit at different stages of evolution, and that is what's fueling the growth. Some markets are below 25 million or 30 million, where growth rates can be significantly higher, and some are above 50 million, where growth rates might be, you know, perhaps in the mid-teens. So that's what's driving the overall growth. It's broad-based growth, and we're pleased with the progress we've made in the ex-U.S. markets.

Nitin Agarwal

analyst
#29

And Badree, when it comes to profitability, how do these markets stack up against the U.S. taken as a block?

Badree Komandur

executive
#30

It ought to be a bit above the corporate average for EBITDA, since that hinges on both the B2B and B2C markets. All in all, I'd say gross margins and EBITDA look solid in those markets.

Nitin Agarwal

analyst
#31

And second, regarding the U.S., you mentioned that things are catching up with some delay, and that the emphasis is more on a few of these differentiated products. So when do you expect the meaningful contribution from these new differentiated products to start delivering?

Badree Komandur

executive
#32

It will definitely happen in FY ’28-’29. That is our target. This represents just a minor slippage of roughly three or four quarters, and we ought to reach that — arrive at that milestone — by FY ’29.

Nitin Agarwal

analyst
#33

Alright, thanks a lot.

Badree Komandur

executive
#34

Thanks.

Operator

operator
#35

Thanks. The next question comes from Pranav at JM AMC. Go right ahead.

Pranav

analyst
#36

Hello, good morning, sir. Can you hear me clearly?

Badree Komandur

executive
#37

Yes, we can hear you.

Pranav

analyst
#38

Let's start with the gross margin question. We've had a sequential decline in gross margin, and you're suggesting that gross margin in the second half will be slightly better. So where does that confidence come from? Has anything in particular shifted compared with the second quarter?

Badree Komandur

executive
#39

Vikesh, would you like to take that one?

Vikesh Kumar

executive
#40

Yeah. So from a quarterly standpoint, many of those purchases that you would have seen coming in Q4, when geopolitical disruptions were at their peak, did get consumed during this quarter. We also had numerous cost initiatives already in place when the geopolitical — when the geopolitical disruptions hit. Those have begun to pay off. We see — we see them internally. And that's what we expect should begin to show from H2 as well. Which is why we're confident that margins at 58% are sustainable.

Pranav

analyst
#41

To build on that, do you figure Q3 will come in stronger than Q2, and Q4 stronger than Q3? In other words, are you anticipating a step-by-step gain, or more of a sudden jump in the fourth quarter, or something along those lines?

Vikesh Kumar

executive
#42

What I'd say is that our emphasis stays on EBITDA and PAT, and those are the metrics we'll keep concentrating on. Over the past several quarters, our push has increasingly been toward generating growth sequentially, and we'll carry on focusing on that, you know. So if you look at the trajectory over a longer term, you'll find that we grow from one quarter to the next.

Pranav

analyst
#43

Alright. Now, regarding the guidance we pushed out to FY ’28 — does that outlook depend on, say, a specific group of products? And if so, could you name the product?

Vikesh Kumar

executive
#44

To start with, that wasn’t guidance. What we described was an aspiration.

Pranav

analyst
#45

Yeah, aspiration is right.

Vikesh Kumar

executive
#46

That was the goal we were aiming toward — reaching FY ’28, you know. That’s what we were pursuing. Given the geopolitical disruptions that have occurred over the past few quarters, and the fact that shortages are no longer as significant in the U.S. within the product portfolio we operate in, we didn’t want to launch products in a way that compromised our discipline around profitability. That’s why we felt it was better to safeguard margin quality and concentrate on profitability — driving the profitability and EPS margin accretion we’ve been recognized for over many quarters. And that’s what we continue to focus on.

Pranav

analyst
#47

So when it comes to that aspiration piece, does it depend on one specific product, one particular big opportunity, or is the basis for it wider than that?

Vikesh Kumar

executive
#48

This isn’t tied to any one product. The trend is broader than that, and we also discussed the portfolio we’re developing, which should begin to show results starting in FY ’29.

Pranav

analyst
#49

Understood, understood. And sir, what makes you confident that your allocation of quota for controlled substances is going to get better over the next year?

Vikesh Kumar

executive
#50

And really, if you look at the past 2 years or so, we've witnessed steady gains in the quota allocations that we've been given. Now, quota allocations come around twice each year, and each time we've returned with quota allocations along with the record of our sales and the growth, the growth in our sales, we've managed to secure — secure better quota, and that is essentially what's showing up in the business right now, which has gone from 0% to 6% over the past 2 years. It's a very different model from the — from the standard retail products, where you can reach a 20%, 30% market share overnight. This takes time, but then once — once you're in there, it stays sticky. And what we're doing as well is, having taken the lessons from this, we're building a portfolio across this whole controlled substance space. And plus the new product that we're — we're building, they require very limited API quota. That would also give us the ability to ramp up far more quickly than the ramp-up that we've experienced over the past 2 years on the existing portfolio.

Pranav

analyst
#51

Understood. That's great. I really appreciate your taking the time to respond to my questions. Enjoy the rest of your day.

Operator

operator
#52

Thanks. <<operator_script>> Our next question comes from Akshaya Shinde at Centrum Broking. Go ahead, please.

Akshaya Shinde

analyst
#53

Yes, thanks for the chance to speak. So revenue from outside the U.S. has now moved ahead of the U.S. business. From a margin standpoint, how should we think about that shifting geographic mix? And does the larger share coming from markets outside the U.S. have a structural effect on gross margin down the road?

Badree Komandur

executive
#54

Okay, on the total gross margin side, Vikesh pointed out that we'll land within that 58% to 60% range, and we're still holding to that range. When it comes to markets outside the U.S., you've got different kinds of markets — B2B markets, B2C markets — sitting at various profitability levels, and our view is that overall, each market will be healthy on margins, and at the company level we'll stay within the range.

Akshaya Shinde

analyst
#55

Got it. Now that the company is carrying more inventory in order to deal with the supply chain situation as it stands, should we be expecting working capital needs to stay elevated, or do you anticipate the cash conversion cycle getting better in the coming few quarters?

Badree Komandur

executive
#56

Sure, the cash conversion cycle is going to get better over the next few quarters. But as you're aware, the past six months have been tough for every company—every business in this space—with longer lead times for raw materials and the key starting materials. And for most companies, all of us included, the main goal is to keep operations running and preserve growth. That's why we've built up inventory levels. We think that will also become a new normal at some point. What you're seeing right now is somewhat extended, but all of this will ease as we move forward and finish out this year. We believe the cash cycle engines should be back in the next quarter itself.

Akshaya Shinde

analyst
#57

Alright, alright. And then finally, regarding the interest cost. So with the higher working capital borrowings and the resulting rise in interest cost for the quarter, should we expect this finance cost to stay elevated for H2 FY ’27 as well?

Badree Komandur

executive
#58

It's going to fall somewhere in the INR40 crores to INR45 crores range. That range is where it should land, and I believe this quarter came in at roughly INR46 crores, if my memory is right. 43, yeah. So it'll sit between INR40 crores and INR45 crores.

Akshaya Shinde

analyst
#59

Alright, got it. Appreciate it — that’s all I had, and best of luck.

Badree Komandur

executive
#60

Appreciate it.

Operator

operator
#61

Thanks. Our next question comes from Karan Shah at GeeCee. Go right ahead.

Karan Shah

analyst
#62

Hi, thanks for giving me the chance to ask. So I have two questions. I believe on the first quarter call we mentioned that the ex-U.S. business had seen some revenue deferment. So could you quantify how much of that might have flowed through into the second quarter?

Badree Komandur

executive
#63

So the flow-through — actually, we had mentioned this, and I think there's a slight point where I should give you clearer detail. From Q2 to Q1, okay, some supply problems came up. Those have all been resolved, and that's what the growth reflects. And if you look at it closely — what it means is this is a very sticky business, and we've resolved all the revenue recognition issues we had, whatever they were, stemming from the long lead times that kept us from getting products there on schedule; all of that has been normalized and it's back to growth.

Karan Shah

analyst
#64

So is it fair to view this as a new run rate excluding Sandoz?

Badree Komandur

executive
#65

Yes.

Karan Shah

analyst
#66

Then moving to the second question, which is about capex — do you have any guidance for FY ’27 and ’28? What would capex be for you?

Badree Komandur

executive
#67

Vikesh, do you want to address that?

Vikesh Kumar

executive
#68

Yeah, I mean, it ought to come in at roughly the INR 300 crores level. I mean, we've — if you look at how our spending has gone down from Q1 to Q2, and we expect it to land, you know, nearer to that INR 300 crores figure by year-end.

Karan Shah

analyst
#69

And what about FY ’28 — same story?

Vikesh Kumar

executive
#70

Sure, FY ’28 might come in a bit lower,

Karan Shah

analyst
#71

A large portion of that would be allocated toward intangibles, since I don’t believe we’ll need much beyond maintenance.

Vikesh Kumar

executive
#72

Yes — there’s maintenance capex that keeps going, so that will be maintenance capex, plus a few portions going to intangibles. Yeah.

Karan Shah

analyst
#73

Alright, thanks for giving me the chance to speak.

Operator

operator
#74

Thanks. <<operator_script>> Our next question comes from Pratik with Unique PMS. The line is yours — go ahead.

Pratik Kothari

analyst
#75

Hello again, and thanks. Regarding the first half, we’re seeing roughly INR265 crores of capex in our cash flow. So is the IP purchases included in that, and does it come through here?

Vikesh Kumar

executive
#76

So yes, regarding the 260 — what separates the INR200 crores from the INR260 crores is INR60 crores of payments tied to all those investments made last year. Those cash flows went out during the first half.

Pratik Kothari

analyst
#77

Okay, but does that 200 figure cover the IP purchase? And this is…

Vikesh Kumar

executive
#78

Correct — IP purchases are part of that too. That covers buying IP along with the money we're putting into nasal sprays and patches.

Pratik Kothari

analyst
#79

Right. And even in the prior year, we completed a handful of IP acquisitions and some outside R&D collaborations, Sandoz among them. So when do those begin to add? Or with Sandoz, I think that one hasn't yet, but for the others, when does that kick in?

Vikesh Kumar

executive
#80

So, some of those are aimed at our global markets, and as far as ex-U.S. goes, they're already playing out. A few of the U.S. specifics, you know, will come through. Actually, we're going to launch our first patch later this year — that was an acquired IP last year. So as far as the U.S. is concerned, some of these will begin to flow through over roughly the next 18 months. But where ex-U.S. is concerned, it is already playing out.

Pratik Kothari

analyst
#81

Right. So over the past 6 to 8 quarters, we've essentially stepped up what we're putting into the business — whether that's capex, IP purchases, the acquisitions, the R&D programs — and that's more or less held our debt levels within a similar band. Earlier, we had some ambition of becoming debt-free, or net debt-free, by a certain point. So has that shifted? Are we pushing it further out? What I mean is, are we now opting to invest more instead of paying down debt, and perhaps we're already at levels we're comfortable with. FY ’28 or ’29, I believe, was the guidance or aspiration we had previously.

Vikesh Kumar

executive
#82

So that goal hasn’t changed at all. And when you examine where the rise in debt has come from, working capital rather than capex accounts for most of it, correct? Our working capital went up by roughly INR300 crores during the first half, and close to INR170 crores of that stemmed from geopolitical disruptions, which was more of a one-time item. So this clearly isn’t a permanent situation. Therefore our ambition stays the same: growth on a consolidated basis remains intact, even though the split between U.S. and ex-U.S. has shifted. On a consolidated basis it holds, and that will show up in our cash flows and debt. And as we reach ’29, it will mostly continue to be working capital debt.

Pratik Kothari

analyst
#83

Right. But that plan to be debt-free — it included working capital debt, didn't it? Or was that excluded from it?

Vikesh Kumar

executive
#84

Sure — when you work through those cash flows, that's the conclusion you'll land on, correct?

Pratik Kothari

analyst
#85

No.

Vikesh Kumar

executive
#86

Basically, what you're seeing is the same thing—that uptick. If you look across the last 4 or 4 quarters, our debt has gone down each quarter, correct? This is the first quarter in which you're seeing debt go up. That rise in debt is mostly tied to the—to the working capital. So, you know, if we make an adjustment for that one-off item, we will—you'll begin to see, you know, the cash flow. And the cash flow we generate will keep coming over the many quarters ahead as growth, you know, as growth carries on.

Pratik Kothari

analyst
#87

Okay, fair enough. And finally, again, looking at this cash flow statement, there's INR70 crores of some inventory obsolescence cost that we've charged to P&L. So anything on that?

Vikesh Kumar

executive
#88

Oh, nothing — nothing specific like that. I mean, a few of those things are parts of the businesses we run, and I think overall it's roughly, you know, 1%, 1% to 2% of COGS.

Pratik Kothari

analyst
#89

No — INR70 crores for H1, correct.

Vikesh Kumar

executive
#90

It's not—I mean, this is a provisioning movement. It comes more from a reporting requirement that, you know, has been separately called out. So it's a cumulative figure.

Pratik Kothari

analyst
#91

Will that go through the cash flow statement?

Vikesh Kumar

executive
#92

That adjustment sits in the inventory line, within the inventory movement. Previously, if you look back, that inventory movement was net; at this point it's been crossed up for that line. My view is that it's more a matter of presentation.

Pratik Kothari

analyst
#93

Oh, really? All right, all right, that's wonderful. Thanks a lot. Best of luck. Thanks.

Operator

operator
#94

Thanks. <<operator_script>> Our next question comes from Kusum Agarwal <<inaudible>>, an individual investor. Go right ahead.

Kusum Agarwal

analyst
#95

Hi there. My question was about how visible the H2 U.S. launches are. The deck mentions that H2 is going to be a strong — it will be stronger thanks to new launches. I just wanted some clarity on how many approvals and launches we should expect during the second half of the financial year?

Badree Komandur

executive
#96

Vikesh, would you like to take that one?

Vikesh Kumar

executive
#97

So we’re looking at launching four to six products, but what matters even more is that the ones we’ve already introduced will start bringing in revenue during H2 as well — which is why we anticipate H2 being stronger than H1. And those H2 launches, you know, will carry over into FY ’28. Right, and that’s when we’ll get a full year of benefit for FY ’28.

Kusum Agarwal

analyst
#98

Alright, sir, that clears up what I was asking. Thank you very much.

Operator

operator
#99

Thank you. <<operator_script>> Our next question comes from Jay <<inaudible>>, who is with Equitas. Please go ahead.

Jay

analyst
#100

Hey Badree. I wanted to ask about our U.S. business — in dollar terms it was actually flat this quarter. So are we seeing significant price erosion, or is it because, you know, we've discontinued a few products due to margin requirements? Like, what's the reason revenue came in flat year-on-year?

Vikesh Kumar

executive
#101

Look, in terms of revenue, when you look at it in dollar terms — in dollar terms, it's flat, and that has more to do with the product mix. And the second thing is that pricing in the market also gets adjusted for the currency depreciation that occurs, you know, because of competitive forces. Because, as you know, in the U.S. market, customers are, you know, always wanting — wanting the best pricing. So that does get adjusted, and that's where we stay focused on delivering the gross margin and maintaining pricing discipline and the profitability threshold, you know, as a framework as we run our P&Ls.

Jay

analyst
#102

So the main factor there is price erosion, correct? And our new launches are probably offsetting that?

Vikesh Kumar

executive
#103

Plus the plans for improving costs that we set up.

Jay

analyst
#104

Right, but that's going to land at the low end of the range. What I'm asking about is the high end — INR 73 million, that figure was INR 73 million. So essentially, we're offsetting price erosion through new launches. That's the whole story, correct?

Vikesh Kumar

executive
#105

This won't be solely about price erosion. There will also be, you know, certain volumes that we let go of as well, correct? So both factors are involved. So, you know, the price erosion might not be quite as significant.

Jay

analyst
#106

Alright, alright, I understand. And somewhere in the PPT, you brought up that, you know, we're seeing — we're observing that drug shortages have normalized. And do you figure that's more nature, or do you think those shortages <<inaudible>>.

Abhishek Singhal

executive
#107

Jay, we lost you a bit — we can’t hear you well. Could you please repeat your question?

Jay

analyst
#108

Okay, so I just wanted to ask — in the PPT you said the opportunities from drug shortages have mostly gone away. So should we expect that to stay the same, or do you think shortages might return once price erosion happens?

Vikesh Kumar

executive
#109

Well, I mean, look, that's more of a — at this stage, that would be more tactical, and that's exactly where we're shifting toward building a more strategic portfolio orientation. And when it comes to the shortages, supply levels throughout the industry have gotten significantly better over the last couple of years. The count of regulatory approvals has gone up. And, you know, that's essentially what has resulted in very minimal shortages across most of the oral products out there. I mean, the shortages we're seeing are either in injectables or in patches, you know, those keep having shortages. So right now, we're more focused on building that portfolio that can carry us and give greater predictability to our growth.

Jay

analyst
#110

Understood, understood. And just briefly regarding controlled substances: so, as you mentioned, each time we return to the regulator to request an increased quota, we have always received it — so that extra volume you're obtaining comes from the market shifting share away from other competitors in the market <<inaudible>>.

Vikesh Kumar

executive
#111

Your voice is coming through loud and clear.

Jay

analyst
#112

Is this coming through clearly at your end now?

Vikesh Kumar

executive
#113

Sure.

Jay

analyst
#114

So just briefly on the controlled substance side — when we talk about that, whenever we visit the regulator two times a year and secure increased quotas, that larger volume you're seeing: is it because the market itself is growing, or do you figure it's more tied to picking up market share from other participants in the market?

Vikesh Kumar

executive
#115

It really comes down to the share gains we've achieved in the market.

Jay

analyst
#116

Understood, understood. Thanks. And then one final quick item about LATAM — I just want to get a sense of your view on that region. Do you see it potentially becoming meaningful across the years? Also, how intense is competition in those markets? We're aware that a handful of listed players are quite strong there, but what exactly is our approach as we move into the Latin American markets?

Badree Komandur

executive
#117

I’m able to address that. We’re currently in the regulatory stage of this market, and building it out—if we do at all—will require a couple of years. I mean, we’ve begun establishing those markets, but I don’t expect them to add meaningfully to any growth until around ’29, ’29-’30, perhaps the first year, and we are in the process of building the portfolio.

Jay

analyst
#118

Understood, understood. That's all I have to share. Thanks.

Badree Komandur

executive
#119

Appreciate it.

Operator

operator
#120

Much appreciated. That wrapped up the final question for today, so at this point I'll pass things over to the management team for their closing remarks.

Badree Komandur

executive
#121

Thanks to all of you, and good day. Appreciate it.

Operator

operator
#122

Thank you. That brings this conference to a close on behalf of Strides Pharma Science Limited.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Strides Pharma Science Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Strides Pharma Science Limited earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Strides Pharma Science Limited or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.